Objective: Aim of the study is to evaluate the role of vulvovaginal injection of a cross-linked HA in patients surgically treated for cancer affected by vulvovaginal symptomatology. Methods: 23 post menopausal patients treated for endometrial cancer with vulvovaginal symptoms were treated. We performed multiple spots injections of 1ml HA with 30Gx1/2 in needle (T1), repeated after 3 months (T2). Self-evaluation using a visual analog scale and investigators evaluation were recorded one month after each treatment. Results: After T1, improvement in vulvovaginal dryness, vulval itching, burning and dyspareunia were reported. At T2, further reduction of symptoms. No side effects were recorded. Conclusions: HA injection is a new, effective adjuvant therapy of postmenopausal vulvovaginal symptoms (above in women after cancer, with hormonal treatment not recommended).
Treatment results for pineal region tumors: role of stereotactic biopsy plus adjuvant therapy vs. open resection
